Mivael Olivera Hurtado de Mendoza

5PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursPredictive and prognostic markersMolecular targetsForensic epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Lisa Licitra, Makoto Tahara, Kevin Harrington

|Jan 12, 2026
Giant Primary Hepatic Endodermal Sinus Tumor: Multidisciplinary Management and Long-Term Survival.

Katia Roque, Rossana Ruiz, Renier Cruz

|Nov 01, 2023
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.

Bradley J Monk, Nicoletta Colombo, Krishnansu S Tewari

|Nov 12, 2022
Real-world outcomes of anti-EGFR therapy in advanced non-small cell lung cancer EGFR mutated in Peru.

Marco Galvez-Nino, Rossana Ruiz, Katia Roque

|Dec 28, 2020
Epidemiology of thymic epithelial tumors: 22-years experience from a single-institution.

Patricia Rioja, Rossana Ruiz, Marco Galvez-Nino

Pageof 1

Frequent Collaborators

3 joint publications

Rossana Ruiz

3 joint publications

Marco Galvez-Nino

3 joint publications

Natalia Valdiviezo

3 joint publications

Luis Mas